Abstract
Despite recent progress in diagnosis and therapy, hepatocellular carcinoma (HCC) remains among the cancers with the poorest prognoses. Vitamin K (VK) have been shown to suppress the growth of HCC cells. Long-term administration of VK(2) has established its clinical safety, but it does not appear to exhibit marked anti-tumor effects when administered alone. For more effective use of VK against HCC, co-administration of VK(2) with other proven anticancer agents or development of a new VK preparation with a modified side-chain should be investigated in the future.
MeSH terms
-
Antineoplastic Agents / pharmacology
-
Antineoplastic Agents / therapeutic use
-
Apoptosis / drug effects
-
Carcinoma, Hepatocellular / drug therapy*
-
Carcinoma, Hepatocellular / pathology
-
Carcinoma, Hepatocellular / prevention & control
-
Cell Division / drug effects
-
Drug Design
-
Drug Synergism
-
Drug Therapy, Combination
-
Humans
-
Liver Neoplasms / drug therapy*
-
Liver Neoplasms / pathology
-
Liver Neoplasms / prevention & control
-
Neoplasm Recurrence, Local / prevention & control
-
Randomized Controlled Trials as Topic
-
Vitamin K 2 / pharmacology
-
Vitamin K 2 / therapeutic use*
Substances
-
Antineoplastic Agents
-
Vitamin K 2